Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide a signed and dated informed consent~2. HIV positive male or female ≥ 18 years of age~3. 50 - 75kg of weight~4. On ATV/rand 2 nucleos(t)ide reverse transcriptase inhibitor containing ART regimen for at least 6 months~5. Undetectable HIV viral load (\<50 copies/ml) at screening PLUS an undetectable VL during the most recent test done between 6 and 12 months prior to screening.~6. A negative pregnancy test for females of child-bearing potential. Should also not be breast feeding.~7. On or willing to use effective contraception for at least 4 weeks prior to enrolment, throughout the study period and at least 4 weeks after end of the study(please see section 10.3 for a detailed definition of effective contraception for this study).~8. Clinically stable with no AIDS defining illness within the past 6 months.~9. A normal chest x-ray~10. Ability and willingness to understand and adhere to the study procedures for the entire study duration.~11. Able to attend for regular study follow-up visits~Exclusion Criteria:~1. Any clinical contraindications to the use of ATV/r, DTG or RIF.~2. Currently receiving treatment for tuberculosis~3. Hepatitis B surface antigen positive or Hepatitis C Antibody positive.~4. Requirement for concomitant medication with known major interactions with study drugs~5. Current participation in another clinical trial or research protocol~6. Symptoms of TB~   * weight loss \> 2.5% in 4 weeks;~  * cough \> 2 weeks;~  * night sweats\> 2 weeks;~  * fever \> 2 weeks;~7. Clinical or laboratory evidence of any of the following:~   * AST/ALT \> 1.5 x the upper limit of normal range (ULN)~  * AST/ALT \> 1.0 x ULN~  * \> 125 mg/dl fasting serum glucose;~  * Serum creatinine ≥ 1.5 X ULN in the absence of dehydration. Or estimated glomerular filtration rate \<60mL/min according to Cockcroft-Gault formula for creatinine clearance.~8. Moderate to severe anaemia (Haemoglobin level \< 8 g/dL)~9. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The investigator should make this determination in consideration of the patient's medical history, clinical and/or laboratory results.~10. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~11. Known chronic underlying disease such as sickle cell disease, diabetes and severe cardiac impairment.~12. Inability to tolerate oral medication, or to drink.~13. Patients taking drugs that are strong inducers of CYP3A4 such as carbamazepine and phenytoin.~14. Known hypersensitivity to any of the agents used in the study~15. Patients with prior herbal medication within one week of screening~16. Use of other investigational drugs within 30 days of enrolment~17. Patients taking medications prohibited by the protocol (see appendix 5)~18. History of substantial use of alcohol that interferes with expected normal activities as determined by the investigator. Additionally, alcohol should be avoided throughout the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dose escalation sequence (all participants) (Type: OTHER): The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).